Acura licenses meth-resistant PSE technology to Bayer
PALATINE, Ill. — Acura Pharmaceuticals Inc. has licensed its methamphetamine-resistant pseudoephedrine (PSE) technology to Bayer Healthcare LLC for use in future products. Under the license and development agreement announced Tuesday, Acura will provide an exclusive worldwide license to its Impede technology to Bayer for use in an undisclosed meth-resistant, PSE-containing product and to jointly develop
